Capricor Therapeutics

NASDAQ: CAPR ↗$23.80 USD~$300M MCAP

#Rare Disease #Cell Therapy #Cardiology #Musculoskeletal

Capricor Therapeutics (NASDAQ: CAPR) is a cell therapy company headquartered in Beverly Hills, California, USA.

Company Info

Sector:Cell Therapy

Headquarters:Beverly Hills, California, USA

Founded:2005

Website:www.capricor.com/

Upcoming Milestones & Key Dates

2026-08-11

Earnings

Q2 2026 earnings

2026-09-30

Regulatory

FDA AdComm for deramiocel (DMD cardiomyopathy)

2026-12-15

Regulatory

PDUFA target for deramiocel

Clinical Development Pipeline

Deramiocel (CAP-1002)

Target: Cardiosphere-derived cells

Duchenne muscular dystrophy cardiomyopathy

Preclinical

Phase 1

Phase 2

Phase 3

Approved

CAP-1002

Target: Cardiosphere-derived cells

DMD skeletal muscle

Preclinical

Phase 1

Phase 2

Phase 3

Approved

StealthX

Target: Engineered exosome

Hypoplastic left heart syndrome

Preclinical

Phase 1

Phase 2

Phase 3

Approved

Capricor thrown for another loop as FDA sets adcomm for DMD cardiomyopathy therapy ↗

Capricor thrown for another loop as FDA sets adcomm for DMD cardiomyopathy therapy.

Leadership Team

Linda Marbán

CEO & Co-founder

AJ Bergmann

CFO

Karen B. Goldschmidt, MD

VP, Clinical Operations

Careers & Job Openings

See all open roles

Multiple Departments

Various

Apply Now →